New COVID-19 variant PJ.2.1 spreads across countries: Symptoms, risks and what the research says

COVID-19 may no longer dominate daily headlines, but the virus has not stopped evolving. A newly identified lineage, PJ.2.1, is attracting attention after appearing in several countries and displaying genetic changes that researchers are examining closely. Does this mean another major wave is approaching? Are existing vaccines still useful? And should people in India be concerned?

Here is what current research and public health surveillance tell us about the variant.

What is the new COVID-19 variant PJ.2.1?

PJ.2.1 is a lineage of SARS-CoV-2, the virus responsible for COVID-19. Researchers describe it as a saltation variant, meaning it emerged with a relatively large number of genetic changes rather than accumulating mutations gradually.

A study published in the Journal of Infection on October 24, 2026, by researchers including Markus Hoffmann and colleagues, traced its origins to MC.10.1.7, a descendant of the JN.1 lineage. Its first documented sample was collected in Ontario, Canada, on May 2, 2026.

Where has PJ.2.1 been detected? Is it spreading globally?

After its initial detection in Canada, PJ.2.1 was identified in several US states and countries including Spain, France, Israel, Singapore, Australia and New Zealand.

Public Health Ontario's genomic surveillance data showed that PJ.2.1 accounted for 25.2% of sequenced SARS-CoV-2 samples between September 20 and October 17, up from 16.9% in the preceding four-week period.

Hong Kong's Centre for Health Protection also reported PJ.2.1 within its JN.1 lineage surveillance data in its November 5 update. However, that figure represents the broader JN.1 group, not PJ.2.1 alone.

Why is the PJ.2.1 variant attracting scientific attention?

The key question is how effectively the variant can enter human cells. SARS-CoV-2 uses its spike protein to attach to a receptor called ACE2, which is present on human cells.

The Journal of Infection study found that PJ.2.1 appeared to bind more efficiently to ACE2 in laboratory experiments. This characteristic could help explain its growth, although laboratory findings alone cannot establish how easily it spreads between people.

Researchers also examined its ability to evade antibodies. They found no substantial additional immune escape compared with most of the other variants tested.

What are the symptoms of the PJ.2.1 COVID-19 variant?

There is currently no confirmed symptom pattern unique to PJ.2.1. According to the World Health Organization (WHO), common COVID-19 symptoms include: Fever and chills, sore throat, persistent cough, runny or blocked nose, headache and body aches, fatigue and weakness, shortness of breath, nausea, vomiting or diarrhoea. Some people may also experience changes in their sense of taste or smell.

The WHO cautions that COVID-19 symptoms can overlap with those of influenza and other respiratory infections. Symptoms alone cannot reliably establish which virus has caused an illness; testing may be necessary.

Is PJ.2.1 more dangerous than previous COVID-19 variants?

There is not enough clinical evidence to conclude that PJ.2.1 causes more severe disease, hospitalisations or deaths.

The research published in the Journal of Infection primarily examined the variant's genetic characteristics, cell entry and antibody sensitivity. It did not establish that people infected with PJ.2.1 are more likely to develop serious complications.

Older adults, people with weakened immune systems and those with underlying conditions such as diabetes, heart disease and chronic respiratory illnesses remain at greater risk of severe COVID-19.

Do existing COVID-19 vaccines protect against PJ.2.1?

The laboratory findings offer some reassurance. Researchers found that antibodies from people who had received an LP.8.1-adapted COVID-19 vaccine could neutralise PJ.2.1. Its sensitivity to neutralisation was 1.8 times lower than that of the LP.8.1 reference variant.

This suggests that the variant has not demonstrated a dramatic ability to escape vaccine-induced antibodies. However, laboratory neutralisation results do not establish how well a vaccine prevents infection in everyday conditions.

The WHO continues to recommend COVID-19 vaccination for people at highest risk of severe disease, including older adults and individuals with certain underlying conditions.

Has PJ.2.1 been detected in India? Should people be worried?

There is currently no verified public confirmation that PJ.2.1 has been detected in India. The Indian SARS-CoV-2 Genomics Consortium (INSACOG) monitors changes in circulating coronavirus strains through a network of sequencing laboratories, but its publicly available dashboard does not identify PJ.2.1 as a confirmed Indian detection.

There is also an important distinction in the WHO's classification. Its latest published variant-tracking information lists JN.1 as a variant of interest and XFG, NB.1.8.1, PQ.16.1.1 and BA.3.2 as variants under monitoring. PJ.2.1 is not separately listed in those categories.

For now, the emergence of PJ.2.1 calls for continued surveillance rather than alarm. Maintaining vaccination among vulnerable groups, practising good respiratory hygiene and seeking medical advice when symptoms become concerning remain sensible precautions. The research is still developing, and whether this lineage will have a significant impact on global COVID-19 trends remains to be seen.

(With inputs from ANI)